Mutant Nogo Receptor Polypeptides Suppress Axonal Growth Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for treating central nervous system (CNS) injuries and diseases, such as spinal cord injuries and multiple sclerosis, are limited by the inhibition of axonal growth caused by myelin proteins interacting with Nogo receptors, necessitating the development of additional compounds that can inhibit NgR signaling and attenuate myelin-mediated growth cone collapse.
Innovation Solution
The use of mutant Nogo receptor polypeptides, specifically those with amino acid sequences like VPPGDSPPGNGSGPQHINDSPFGTLPGSAE, to suppress axonal growth inhibition in CNS neurons by interfering with the signaling pathways mediated by Nogo receptors, thereby promoting axonal growth in conditions where it is normally inhibited.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If myelin proteins interact with Nogo receptors, then axonal growth is inhibited, but this interaction is necessary for normal neuronal development and myelin function
Solution Approach 1:
The patent introduces mutant Nogo receptor polypeptides as intermediary substances that bind to myelin proteins (Nogo-A, MAG, OM-gp) and prevent their interaction with endogenous Nogo receptors on growth cones. These mutant receptors act as decoys or competitive inhibitors, blocking the harmful signaling pathway without affecting normal myelin function, thus resolving the contradiction between promoting axonal growth and maintaining myelin-mediated inhibition for normal development
Solution Approach 2:
The patent modifies the Nogo receptor protein sequence (e.g., R377Q, R377W mutations) to change its binding properties. The mutant receptors have altered affinity and specificity for myelin ligands, allowing them to bind myelin proteins with high affinity but fail to transmit the growth-inhibiting signal. This parameter change in receptor structure enables selective blocking of harmful interactions while preserving beneficial myelin functions
2Reliability
If anti-NogoA antibody IN-1 is used to improve functional recovery, then spinal cord injury recovery is enhanced, but the specificity and efficacy for different myelin proteins are limited
Solution Approach 1:
The patent creates a multi-functional therapeutic approach by developing mutant Nogo receptor polypeptides that can bind to multiple different myelin proteins (Nogo-A, MAG, OM-gp) simultaneously or sequentially. Unlike the monoclonal antibody IN-1 that targets only Nogo-A, these mutant receptors provide broad-spectrum inhibition of myelin-mediated growth cone collapse, enhancing functional recovery reliability while improving adaptability to different injury scenarios and myelin compositions
3Productivity
If NEP1-40 peptide is used to attenuate myelin effects, then growth cone collapse is reduced, but additional compounds are still needed for complete inhibition
Solution Approach 1:
The patent employs a composite therapeutic strategy combining mutant Nogo receptor polypeptides with other potential agents. The mutant receptors serve as a core component that provides broad myelin protein binding capability, while the composite approach allows integration with additional compounds targeting specific pathways or myelin proteins, achieving complete inhibition of growth cone collapse without over-relying on a single agent
Data Source
AI summary
The invention provides compositions and methods for interfering with Nogo-receptor mediated signaling and mediating axonal growth. The invention also provides methods for treating central nervous system diseases, disorders or injuries.